Professor Ric Price, affiliated with our OUCRU unit, tells us of his research on surveillance, diagnostics and treatments for Plasmodium vivax malaria
Curing Plasmodium vivax malaria
Loading Video...
Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.
Series:
People:
Oxford Unit:
More in this Series...
Malaria is an endemic disease in much of the world, and is a major contributor to child and infant mortality in many countries. Our malaria podcasts describe efforts by NDM clinicians and scientists, in Oxford and around the world, to treat and prevent malaria, including vaccine development, parasitology, and improved treatment for severe malaria, with the aim to lessen the disease burden on some of the world's most vulnerable people.
Subscribe
Download Media
- Video (47.94 MB)